Skip to main content
Fig. 3 | BMC Psychiatry

Fig. 3

From: Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study

Fig. 3

Median Change in Prolactin From Double-Blind Baseline Through 6 Months of Open-Label Treatment With Lurasidone, by Treatment Assignment in the Double-Blind Study. 3-A. Males. LUR = lurasidone; RIS = risperidone. *Subgroup entering open-label extension; 6-month completer analysis: LUR-LUR, n = 102; RIS-LUR, n = 68. Patients in the RIS-LUR group received risperidone in the 12-month, double-blind study. 3-B. Females. LUR = lurasidone; RIS = risperidone. *Subgroup entering open-label extension; 6-month completer analysis: LUR-LUR, n = 34; RIS-LUR, n = 29. Patients in the RIS-LUR group received risperidone in the 12-month, double-blind study

Back to article page